Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7…
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15,…
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused…
Newly formed company founded by prominent Yale professors will advance development of novel RNA therapies and vaccine adjuvants for local…
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022 SIGNIFICANT STRATEGIC AND OPERATIONAL PROGRESS TOWARDS BECOMING A…
TNX-1500 Treatment Prevents Organ Rejection and Preserves Function for Both Allograft and Xenograft Transplants in Animal Studies CHATHAM, N.J., Sept.…
Anima Research Center participating in a trial for an investigational RSV vaccine Belgium’s largest clinical trial center encourages continued…
Follows CDC & World Health Organization's (WHO) announcement that US now meets criteria for country with circulating vaccine-derived poliovirus (cVDPV)Surveillance wastewater and…
Data include the persistence of immune responses and protection against variants of concern, especially Delta and OmicronOcugen has North American…
WASHINGTON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today announced it is receiving an additional $21.8 million…